Obesity最新文献

筛选
英文 中文
Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis 利拉鲁肽与西马鲁肽的体重减轻-治疗分析所需的成本
IF 6.9 2区 医学
Obesity Pub Date : 2023-05-19 DOI: 10.1002/oby.23752
Joseph Azuri, Ariel Hammerman, Enis Aboalhasan, Ben Sluckis, Ronen Arbel
{"title":"Liraglutide versus semaglutide for weight reduction—a cost needed to treat analysis","authors":"Joseph Azuri,&nbsp;Ariel Hammerman,&nbsp;Enis Aboalhasan,&nbsp;Ben Sluckis,&nbsp;Ronen Arbel","doi":"10.1002/oby.23752","DOIUrl":"https://doi.org/10.1002/oby.23752","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Higher doses of the glucagon-like peptide-1 agonists liraglutide and, more recently, semaglutide have demonstrated a significant reduction in body weight. However, their comparative value for money for this indication is unclear.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The cost needed to treat to achieve a 1% reduction in body weight using semaglutide or liraglutide was calculated. The body weight reductions were extracted from the published STEP 1 trial and the SCALE trial results, respectively. A scenario analysis was performed to mitigate the primary differences between the two studies' populations. Drug costs were based on US GoodRx prices as of October 2022.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Liraglutide in STEP 1 resulted in a weight loss of 5.4% (95% CI: 5%-5.8%). Semaglutide in SCALE resulted in a weight loss of 12.4% (95% CI: 11.5%-13.4%). The total cost of therapy with liraglutide during the trial was estimated at $17,585 compared with $22,878 with semaglutide. Accordingly, the cost needed to treat per 1% of body weight reduction with liraglutide is estimated at $3256 (95% CI: $3032-$3517) compared with $1845 (95% CI: $1707-$1989) with semaglutide.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Semaglutide provides significantly better value for money than liraglutide for weight reduction.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 6","pages":"1510-1513"},"PeriodicalIF":6.9,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.23752","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"6223927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Betaine–homocysteine methyltransferase promotes adipocyte commitment and insulin resistance via p38 MAPK/Smad signaling 甜菜碱-同型半胱氨酸甲基转移酶通过p38 MAPK/Smad信号传导促进脂肪细胞承诺和胰岛素抵抗
IF 6.9 2区 医学
Obesity Pub Date : 2023-05-19 DOI: 10.1002/oby.23737
Chuchu Liu, Yao Zhang, Yanping Wang, Ning Wang, Junting Xu, Xingxing Liang, Jie Xiong, Sijia Lu, Peihui Zhou, Junli Liu, Suzhen Chen
{"title":"Betaine–homocysteine methyltransferase promotes adipocyte commitment and insulin resistance via p38 MAPK/Smad signaling","authors":"Chuchu Liu,&nbsp;Yao Zhang,&nbsp;Yanping Wang,&nbsp;Ning Wang,&nbsp;Junting Xu,&nbsp;Xingxing Liang,&nbsp;Jie Xiong,&nbsp;Sijia Lu,&nbsp;Peihui Zhou,&nbsp;Junli Liu,&nbsp;Suzhen Chen","doi":"10.1002/oby.23737","DOIUrl":"https://doi.org/10.1002/oby.23737","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Betaine–homocysteine methyltransferase (Bhmt) belongs to the family of methyltransferases and is involved in the one-carbon metabolic cycle, which is associated with the risk of diabetes and adiposity. This study aimed to explore whether Bhmt participated in the development of obesity or its associated diabetes, as well as the mechanism involved.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The expression levels of Bhmt were examined in stromal vascular fraction cells and mature adipocytes in obesity and nonobesity. Knockdown and overexpression of Bhmt in C3H10T1/2 cells were used to investigate Bhmt's function in adipogenesis. Bhmt's role <i>in vivo</i> was analyzed using an adenovirus-expressing system and a high-fat diet–induced obesity mouse model.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Bhmt was highly expressed in stromal vascular fraction cells rather than mature adipocytes of adipose tissue and was upregulated in adipose tissue in obesity and C3H10T1/2-commited preadipocytes. Overexpression of Bhmt promoted adipocyte commitment and differentiation <i>in vitro</i> and exacerbated adipose tissue expansion <i>in vivo</i>, with a concomitant increase in insulin resistance, whereas Bhmt silencing exhibited opposite effects. Mechanistically, Bhmt-induced adipose expansion was mediated by stimulating the p38 MAPK/Smad pathway.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The findings of this study highlight the obesogenic and diabetogenic role of adipocytic Bhmt and propose Bhmt as a promising therapeutic target for obesity and obesity-related diabetes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 6","pages":"1569-1583"},"PeriodicalIF":6.9,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5708323","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Glucose-dependent insulinotropic polypeptide monoclonal antibodies prevent and treat obesity in wild-type and hyperphagic mice 葡萄糖依赖型促胰岛素多肽单克隆抗体预防和治疗野生型和贪食型小鼠肥胖
IF 6.9 2区 医学
Obesity Pub Date : 2023-05-19 DOI: 10.1002/oby.23758
M. Michael Wolfe, Caroline M. Apovian, Michael O. Boylan
{"title":"Glucose-dependent insulinotropic polypeptide monoclonal antibodies prevent and treat obesity in wild-type and hyperphagic mice","authors":"M. Michael Wolfe,&nbsp;Caroline M. Apovian,&nbsp;Michael O. Boylan","doi":"10.1002/oby.23758","DOIUrl":"https://doi.org/10.1002/oby.23758","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This study aimed to investigate whether a glucose-dependent insulinotropic polypeptide (GIP) monoclonal antibody (mAb) will promote weight loss in wild-type mice and to determine effects of this mAb in preventing weight gain in <i>ob</i>/<i>ob</i> mice.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Phosphate-buffered saline (PBS) or GIP mAb was injected intraperitoneally to wild-type mice fed a 60% high-fat diet (HFD). After 12 weeks, mice that received PBS were divided into two groups and were fed a 37% HFD for 5 weeks; one group received PBS, and one group received GIP mAb. In a separate study, PBS or GIP mAb was injected intraperitoneally to <i>ob</i>/<i>ob</i> mice fed normal mouse chow for 8 weeks.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>PBS-treated mice gained significantly more than those treated with GIP mAb, with no difference in food consumption detected. Obese mice fed a 37% HFD and PBS continued to gain weight (+2.1% ± 0.9%), whereas mice administered GIP mAb lost 4.1% ± 1.4% body weight (<i>p</i> &lt; 0.01). Leptin-deficient mice consumed similar amounts of chow, and, after 8 weeks, the PBS- and GIP mAb-treated mice gained 250.4% ± 9.1% and 192.4% ± 7.3%, respectively (<i>p</i> &lt; 0.01).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These studies support the hypothesis that a reduction in GIP signaling appears to affect body weight without suppressing food intake and might provide a novel, useful method for the treatment and prevention of obesity.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 6","pages":"1499-1504"},"PeriodicalIF":6.9,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.23758","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5933775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A South Asian Mediterranean-style diet is associated with favorable adiposity measures and lower diabetes risk: The MASALA cohort 南亚地中海式饮食与有利的肥胖措施和较低的糖尿病风险相关:MASALA队列
IF 6.9 2区 医学
Obesity Pub Date : 2023-05-19 DOI: 10.1002/oby.23759
Sharan K. Rai, Steven L. Gortmaker, Frank B. Hu, Alka M. Kanaya, Namratha R. Kandula, Qi Sun, Shilpa N. Bhupathiraju
{"title":"A South Asian Mediterranean-style diet is associated with favorable adiposity measures and lower diabetes risk: The MASALA cohort","authors":"Sharan K. Rai,&nbsp;Steven L. Gortmaker,&nbsp;Frank B. Hu,&nbsp;Alka M. Kanaya,&nbsp;Namratha R. Kandula,&nbsp;Qi Sun,&nbsp;Shilpa N. Bhupathiraju","doi":"10.1002/oby.23759","DOIUrl":"https://doi.org/10.1002/oby.23759","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The Mediterranean diet is associated with lower risks for type 2 diabetes (T2D) and cardiovascular disease in certain populations, although data among diverse groups are limited. This study evaluated cross-sectional and prospective associations between a novel South Asian Mediterranean-style (SAM) diet and cardiometabolic risk among US South Asian individuals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study included 891 participants at baseline in the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. Culturally relevant foods were grouped into nine categories to construct the SAM score. The study examined associations of this score with cardiometabolic risk factors and incident T2D.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At baseline, higher adherence to the SAM diet was associated with lower glycated hemoglobin (−0.43% ± 0.15% per 1-unit increase in SAM score; <i>p</i> = 0.004) and lower pericardial fat volume (−1.22 ± 0.55 cm<sup>3</sup>; <i>p</i> = 0.03), as well as a lower likelihood of obesity (odds ratio [OR]: 0.88, 95% CI: 0.79–0.98) and fatty liver (OR: 0.82, 95% CI: 0.68–0.98). Over the follow-up (~5 years), 45 participants developed T2D; each 1-unit increase in SAM score was associated with a 25% lower odds of incident T2D (OR: 0.75, 95% CI: 0.59–0.95).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A greater intake of a SAM diet is associated with favorable adiposity measures and a lower likelihood of incident T2D.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 6","pages":"1697-1706"},"PeriodicalIF":6.9,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.23759","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5734134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Efficacy and safety of modified fasting therapy for weight loss in 2054 hospitalized patients 2054例住院患者改良禁食减肥疗法的疗效和安全性
IF 6.9 2区 医学
Obesity Pub Date : 2023-05-19 DOI: 10.1002/oby.23756
Taoli Liu, Ziheng Ye, Jiahao Feng, Li Zhang, Hongda Chen, Xianhua Chen, Fangjie Cai, Gengpeng Zhang, Jicai Lai, Zhiyu Ye, Nan Cao, Binyan Mo, Zhiling Li, Ning Wang, Yuejia Lin, Tingying Zhang, Yu Yang, Jianguo Hu, Ling Yan, Zilong Zheng, Wei Song, Haifang Liang, Jian Qin
{"title":"Efficacy and safety of modified fasting therapy for weight loss in 2054 hospitalized patients","authors":"Taoli Liu,&nbsp;Ziheng Ye,&nbsp;Jiahao Feng,&nbsp;Li Zhang,&nbsp;Hongda Chen,&nbsp;Xianhua Chen,&nbsp;Fangjie Cai,&nbsp;Gengpeng Zhang,&nbsp;Jicai Lai,&nbsp;Zhiyu Ye,&nbsp;Nan Cao,&nbsp;Binyan Mo,&nbsp;Zhiling Li,&nbsp;Ning Wang,&nbsp;Yuejia Lin,&nbsp;Tingying Zhang,&nbsp;Yu Yang,&nbsp;Jianguo Hu,&nbsp;Ling Yan,&nbsp;Zilong Zheng,&nbsp;Wei Song,&nbsp;Haifang Liang,&nbsp;Jian Qin","doi":"10.1002/oby.23756","DOIUrl":"https://doi.org/10.1002/oby.23756","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The aim of this study was to evaluate the efficacy and safety of modified fasting therapy, and a retrospective study was conducted to analyze changes in clinical indicators of hospitalized fasting patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>A total of 2054 hospitalized fasting patients were enrolled in this observational study. All participants underwent 7 days of modified fasting therapy. The clinical efficacy biomarkers, safety indicators, and body composition were measured before and after fasting.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The modified fasting therapy reduced body weight, BMI, abdominal circumference, systolic blood pressure, and diastolic blood pressure significantly. Blood glucose and indicators of body composition were improved to various extents (all <i>p</i> &lt; 0.05). There was a small increase in liver function, kidney function, uric acid, electrolytes, blood count, coagulation, and uric biomarkers. Subgroup analysis results showed that cardiovascular diseases benefited from modified fasting therapy.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>At present this study is the largest retrospective population-based study about modified fasting therapy. The results from 2054 patients showed that the modified fasting therapy lasting 7 days was efficient and safe. It led to improvements in physical health and body weight-associated indicators, as well as body composition and relevant cardiovascular risk factors.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 6","pages":"1514-1529"},"PeriodicalIF":6.9,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5732618","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Neural correlates of decreased impulsivity during delay discounting task after laparoscopic sleeve gastrectomy 腹腔镜袖胃切除术后延迟折扣任务中冲动性降低的神经相关研究
IF 6.9 2区 医学
Obesity Pub Date : 2023-05-19 DOI: 10.1002/oby.23763
Wenchao Zhang, Guanya Li, Yang Hu, Jia Wang, Weibin Ji, Karen M. von Deneen, Juan Yu, Yu Han, Guangbin Cui, Peter Manza, Dardo Tomasi, Nora D. Volkow, Huaning Wang, Yongzhan Nie, Gang Ji, Gene-Jack Wang, Yi Zhang
{"title":"Neural correlates of decreased impulsivity during delay discounting task after laparoscopic sleeve gastrectomy","authors":"Wenchao Zhang,&nbsp;Guanya Li,&nbsp;Yang Hu,&nbsp;Jia Wang,&nbsp;Weibin Ji,&nbsp;Karen M. von Deneen,&nbsp;Juan Yu,&nbsp;Yu Han,&nbsp;Guangbin Cui,&nbsp;Peter Manza,&nbsp;Dardo Tomasi,&nbsp;Nora D. Volkow,&nbsp;Huaning Wang,&nbsp;Yongzhan Nie,&nbsp;Gang Ji,&nbsp;Gene-Jack Wang,&nbsp;Yi Zhang","doi":"10.1002/oby.23763","DOIUrl":"https://doi.org/10.1002/oby.23763","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The goal of this study was to investigate laparoscopic sleeve gastrectomy (LSG)-induced changes in choice impulsivity and the neural correlates in individuals with obesity (OB).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The study employed functional magnetic resonance imaging with a delay discounting task in 29 OB tested before and 1 month after LSG. Thirty participants with normal weight matched to OB with gender and age were recruited as the control group and underwent an identical functional magnetic resonance imaging scan. Alterations in activation and functional connectivity between pre- and post-LSG were investigated and compared with participants with normal weight.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>OB exhibited significantly reduced discounting rate after LSG. During the delay discounting task, hyperactivation in dorsolateral prefrontal cortex, right caudate, and dorsomedial prefrontal cortex decreased in OB after LSG. LSG additionally engaged compensatory effects through increased activation in bilateral posterior insula and functional connectivity between caudate and dorsomedial prefrontal cortex. Those changes were associated with decreased discounting rate and BMI as well as improved eating behaviors.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>These findings indicate that decreased choice impulsivity following LSG was associated with the changes in regions involved in executive control, reward evaluation, interoception, and prospection. This study may provide neurophysiological support for the development of nonoperative treatments such as brain stimulation for individuals with obesity and overweight.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 6","pages":"1634-1643"},"PeriodicalIF":6.9,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"6222787","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility of time-restricted eating in individuals with overweight, obesity, prediabetes, or type 2 diabetes: A systematic scoping review 限时饮食对超重、肥胖、糖尿病前期或2型糖尿病患者的可行性:一项系统的范围综述
IF 6.9 2区 医学
Obesity Pub Date : 2023-05-19 DOI: 10.1002/oby.23743
Anne-Ditte Termannsen, Annemarie Varming, Christina van Elst, Natasja Bjerre, Ole N?rgaard, Nana Folmann Hempler, Kristine F?rch, Jonas Salling Quist
{"title":"Feasibility of time-restricted eating in individuals with overweight, obesity, prediabetes, or type 2 diabetes: A systematic scoping review","authors":"Anne-Ditte Termannsen,&nbsp;Annemarie Varming,&nbsp;Christina van Elst,&nbsp;Natasja Bjerre,&nbsp;Ole N?rgaard,&nbsp;Nana Folmann Hempler,&nbsp;Kristine F?rch,&nbsp;Jonas Salling Quist","doi":"10.1002/oby.23743","DOIUrl":"https://doi.org/10.1002/oby.23743","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>This systematic scoping review aimed to map and synthesize research on feasibility of time-restricted eating (TRE) in individuals with overweight, obesity, prediabetes, or type 2 diabetes, including recruitment rate, retention rate, safety, adherence, and participants' attitudes, experiences, and perspectives.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The authors searched MEDLINE, Embase, and Cumulative Index to Nursing and Allied Health Literature from inception to November 22, 2022, supplemented by backward and forward citation search.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>From 4219 identified records, 28 studies were included. In general, recruitment was easy and median retention rate was 95% among studies with &lt;12 weeks duration and 89% among studies ≥12 weeks. Median (range) adherence to the target eating window for studies &lt;12 and ≥12 weeks was 89% (75%–98%) and 81% (47%–93%), respectively. Variation in adherence among participants and studies was considerable, indicating that following TRE was difficult for some people and that intervention conditions influenced adherence. These findings were supported by qualitative data synthetized from seven studies, and determinants of adherence included calorie-free beverages outside the eating window, provision of support, and influence on the eating window. No serious adverse events were reported.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>TRE is implementable, acceptable, and safe in populations with overweight, obesity, prediabetes, or type 2 diabetes, but it should be accompanied by support and options for individual adjustments.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 6","pages":"1463-1485"},"PeriodicalIF":6.9,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.23743","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5708351","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Insulin resistance, cognition, and Alzheimer disease 胰岛素抵抗,认知和老年痴呆症
IF 6.9 2区 医学
Obesity Pub Date : 2023-05-19 DOI: 10.1002/oby.23761
Anne B. Kim, Zoe Arvanitakis
{"title":"Insulin resistance, cognition, and Alzheimer disease","authors":"Anne B. Kim,&nbsp;Zoe Arvanitakis","doi":"10.1002/oby.23761","DOIUrl":"https://doi.org/10.1002/oby.23761","url":null,"abstract":"<p>Chronic diseases of aging are increasingly common. Dementia, often due to multiple etiologies including Alzheimer disease (AD), is at the forefront. Previous studies have reported higher rates of dementia among persons with diabetes, yet less is known about how insulin resistance relates to cognition. This article reviews recently published data on the relationship of insulin resistance to cognition and AD, and remaining knowledge gaps in the field are discussed. A structured review of studies was conducted over a 5-year period, investigating insulin and cognitive function in adults with a baseline mean age of ≥65 years. This search yielded 146 articles, of which 26 met the predetermined inclusion and exclusion criteria. Among the nine studies that specifically examined insulin resistance and cognitive dysfunction and/or decline, eight studies suggest an association, but some only in subanalyses. Results are mixed in studies relating insulin to structural and functional changes on brain imaging, and data on intranasal insulin for cognition remain unclear. Future avenues are proposed to elucidate the impact of insulin resistance on brain structure and function, including cognition, in persons with and without AD.</p>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 6","pages":"1486-1498"},"PeriodicalIF":6.9,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.23761","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5933790","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Targeting peroxisome proliferator-activated receptor γ proteasomal degradation by magnolol is a potential avenue for adipogenesis-mediated metabolic homeostasis 厚朴酚靶向过氧化物酶体增殖物激活受体γ蛋白酶体降解是脂肪生成介导的代谢稳态的潜在途径
IF 6.9 2区 医学
Obesity Pub Date : 2023-05-19 DOI: 10.1002/oby.23727
Peng-Long Li, Mei Li, Zhenya Wang, Xiao-Ming Wang, Shuai-Yang Liu, Song Tian, Zhou-Xiang Wang, Xu Cheng, Yufeng Hu, Peng Zhang, Zhi-Gang She, Hailong Yang, Hongliang Li, Xiao-Jing Zhang
{"title":"Targeting peroxisome proliferator-activated receptor γ proteasomal degradation by magnolol is a potential avenue for adipogenesis-mediated metabolic homeostasis","authors":"Peng-Long Li,&nbsp;Mei Li,&nbsp;Zhenya Wang,&nbsp;Xiao-Ming Wang,&nbsp;Shuai-Yang Liu,&nbsp;Song Tian,&nbsp;Zhou-Xiang Wang,&nbsp;Xu Cheng,&nbsp;Yufeng Hu,&nbsp;Peng Zhang,&nbsp;Zhi-Gang She,&nbsp;Hailong Yang,&nbsp;Hongliang Li,&nbsp;Xiao-Jing Zhang","doi":"10.1002/oby.23727","DOIUrl":"https://doi.org/10.1002/oby.23727","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Adipogenesis has been recognized as an attractive avenue for maintaining systemic homeostasis, with peroxisome proliferator-activated receptor γ (PPARγ) showing predominant roles in this process. This study aims to identify promising drug candidates by targeting PPARγ for adipogenesis-based metabolic homeostasis and to clarify the detailed mechanisms.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Molecular events contributing to adipogenesis were screened, which identified PPARγ as having the predominant role. Promising agents of adipogenesis agonism were screened using a PPARγ-based luciferase reporter assay. The functional capacity and molecular mechanisms of magnolol were intensively examined using 3T3-L1 preadipocytes and dietary models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>This study found that F-box only protein 9 (FBXO9)-mediated lysine 11 (K11)-linked ubiquitination and proteasomal degradation of PPARγ are critically required during adipogenesis and systemic homeostasis. Notably, magnolol was identified as a potent adipogenesis activator by stabilizing PPARγ. The pharmacological mechanisms investigations clarified that magnolol directly binds to PPARγ and markedly interrupts its interaction with FBXO9, leading to a decline in K11-linked ubiquitination and proteasomal degradation of PPARγ. Clinically important, magnolol treatment significantly facilitates adipogenesis <i>in vitro</i> and <i>in vivo</i>.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>The downregulation of K11-linked ubiquitination of PPARγ caused by FBOX9 is essentially required for adipogenesis, while targeting PPARγ-FBXO9 interaction provides a new avenue for the therapy of adipogenesis-related metabolic disorder.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 6","pages":"1584-1599"},"PeriodicalIF":6.9,"publicationDate":"2023-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"6222789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg 将青少年BMI降低至肥胖阈值以下,每周一次皮下注射semaglutide 2.4 mg
IF 6.9 2区 医学
Obesity Pub Date : 2023-05-17 DOI: 10.1002/oby.23808
Aaron S. Kelly, Silva Arslanian, Dan Hesse, Aske Thorn Iversen, Antje K?rner, Signe Schmidt, Rasmus S?rrig, Daniel Weghuber, Ania M. Jastreboff
{"title":"Reducing BMI below the obesity threshold in adolescents treated with once-weekly subcutaneous semaglutide 2.4 mg","authors":"Aaron S. Kelly,&nbsp;Silva Arslanian,&nbsp;Dan Hesse,&nbsp;Aske Thorn Iversen,&nbsp;Antje K?rner,&nbsp;Signe Schmidt,&nbsp;Rasmus S?rrig,&nbsp;Daniel Weghuber,&nbsp;Ania M. Jastreboff","doi":"10.1002/oby.23808","DOIUrl":"https://doi.org/10.1002/oby.23808","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>The aim of this study was to examine how improvement in BMI with the glucagon-like peptide-1 receptor agonist semaglutide translated to changes in BMI category in a post hoc analysis of the double-blind, phase 3a randomized controlled Semaglutide Treatment Effect in People with obesity (STEP) TEENS trial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Adolescents with obesity received once-weekly subcutaneous semaglutide 2.4 mg or placebo plus lifestyle intervention, which comprised counseling in healthy nutrition and a goal of 60 minutes of moderate- to high-intensity physical activity per day. Achievement of an improvement in BMI category and attainment of normal-weight or overweight BMI by week 68 were analyzed using logistic regression models.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In the overall population, 44.9% of participants receiving semaglutide achieved weight reduction resulting in reclassification to a normal-weight or overweight BMI category versus 12.1% receiving placebo at week 68 (odds ratio: 22.7; 95% CI: 7.6–67.9). The proportion of semaglutide-treated participants in obesity class III decreased from 37.3% to 13.6% but increased with placebo. The odds ratio for achieving an improvement of at least one BMI category was significantly greater with semaglutide versus placebo (23.5; 95% CI: 9.9–55.5); an improvement of at least one BMI category was seen in 73.7% of participants receiving semaglutide compared with 19.0% of participants receiving placebo.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Semaglutide was highly effective in reducing BMI category. While on treatment, most trial participants' BMI improved by at least one category, and &gt;40% reached a category below the obesity threshold.</p>\u0000 </section>\u0000 </div>","PeriodicalId":215,"journal":{"name":"Obesity","volume":"31 8","pages":"2139-2149"},"PeriodicalIF":6.9,"publicationDate":"2023-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/oby.23808","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"5905815","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信